Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140348
Status:
COMPLETED
Last Update Posted:
2007-12-24
First Post:
2005-08-30
Brief Title:
Dose Escalation and Efficacy Trial of GVAX Prostate Cancer Vaccine
Sponsor:
Cell Genesys
Organization:
Cell Genesys
Study Overview
Official Title:
A Phase III Dose Escalation and Efficacy Trial of GVAX Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX Prostate Cancer Vaccine in order to determine a maximum tolerated dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None